Literature DB >> 23107855

Predictors of survival in patients with non-small cell lung cancer.

Juhua Luo1, Yea-Jyh Chen, Georgia L Narsavage, Alan Ducatman.   

Abstract

PURPOSE/
OBJECTIVES: To examine how routine laboratory biomarkers and clinical parameters available within medical records related to overall survival in patients with non-small cell lung cancer (NSCLC).
DESIGN: Retrospective chart review.
SETTING: University-based cancer center in rural West Virginia. SAMPLE: 110 patients from the U.S. Appalachian region with a primary diagnosis of NSCLC at initial hospitalization.
METHODS: Electronic medical records were reviewed for one year after discharge or until death. The Kaplan-Meier method was used to compare survival curves for each prognostic factor. Cox proportional hazards model was used for multivariate analyses. MAIN RESEARCH VARIABLES: Total white blood cell, neutrophil, lymphocyte, and platelet counts; hemoglobin level; body mass index (BMI); performance status; and cancer stage.
FINDINGS: Low BMI (lower than 18.5 lb/in2), advanced cancer stage (IIIB or IV), and elevated neutrophil (higher than 8 x 103/mcl) and platelet (300-826 x 1012/L) counts were significant, independent prognostic factors for shorter survival time in NSCLC. BMI (hazard ratio [HR] = 2.15, 95% confidence interval [CI] [0.94, 4.9]) and neutrophil (HR = 2.93, 95% CI [1.53, 5.59]) and platelet (HR = 2.65, 95% CI [1.25, 5.62]) counts were overall prognostic predictors for patients with advanced NSCLC and remained in the multivariate survival model.
CONCLUSIONS: This study detected two known clinical parameters, cancer stage and nutritional status (i.e., BMI and neutrophil and platelet counts), as having independent prognostic significance for shorter survival in NSCLC. Research on survival in patients with NSCLC should include those identified laboratory biomarkers and clinical parameters for screening patients at risk for shorter survival time following hospitalization. Investigation of whether treatments tailored to address neutrophil and platelet counts and BMI can improve survival outcomes also is warranted. IMPLICATIONS FOR NURSING: Attention to common biomarkers recorded in patient charts (e.g., neutrophil and platelet counts) as well as BMI could allow nurses to identify patients at risk for low survival. Interventions should be identified and initiated. Longitudinal studies in clinical settings that follow the survival of patients with NSCLC are essential.

Entities:  

Mesh:

Year:  2012        PMID: 23107855     DOI: 10.1188/12.ONF.609-616

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  12 in total

1.  Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer.

Authors:  Oscar Arrieta; Martha De la Torre-Vallejo; Diego López-Macías; David Orta; Jenny Turcott; Eleazar-Omar Macedo-Pérez; Karla Sánchez-Lara; Laura-Alejandra Ramírez-Tirado; Vickie E Baracos
Journal:  Oncologist       Date:  2015-07-14

2.  Prognostic role of elevated platelet count in patients with lung cancer: a systematic review and meta-analysis.

Authors:  Xi Zhang; Yuge Ran
Journal:  Int J Clin Exp Med       Date:  2015-04-15

3.  Body mass index and mortality in lung cancer patients: a systematic review and meta-analysis.

Authors:  J Wang; H Xu; S Zhou; D Wang; L Zhu; J Hou; J Tang; J Zhao; S Zhong
Journal:  Eur J Clin Nutr       Date:  2017-05-17       Impact factor: 4.016

4.  Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium.

Authors:  Daniel Shepshelovich; Wei Xu; Lin Lu; Aline Fares; Ping Yang; David Christiani; Jie Zhang; Kouya Shiraishi; Brid M Ryan; Chu Chen; Ann G Schwartz; Adonina Tardon; Xifeng Wu; Matthew B Schabath; M Dawn Teare; Loic Le Marchand; Zuo-Feng Zhang; John K Field; Hermann Brenner; Nancy Diao; Juntao Xie; Takashi Kohno; Curtis C Harris; Angela S Wenzlaff; Guillermo Fernandez-Tardon; Yuanqing Ye; Fiona Taylor; Lynne R Wilkens; Michael Davies; Yi Liu; Matt J Barnett; Gary E Goodman; Hal Morgenstern; Bernd Holleczek; M Catherine Brown; Geoffrey Liu; Rayjean J Hung
Journal:  J Thorac Oncol       Date:  2019-06-01       Impact factor: 15.609

5.  Lung cancer stigma as a barrier to medical help-seeking behavior: Practice implications.

Authors:  Lisa Carter-Harris
Journal:  J Am Assoc Nurse Pract       Date:  2015-03-03       Impact factor: 1.165

6.  Pathways to a lung cancer diagnosis.

Authors:  Lisa Carter-Harris; Carla Penrod Hermann; Claire Burke Draucker
Journal:  J Am Assoc Nurse Pract       Date:  2015-03-12       Impact factor: 1.165

7.  Concomitant chemoradiotherapy with docetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unresectable non-small cell lung cancer.

Authors:  Celalettin Eroglu; Okan Orhan; Dilek Unal; Gamze G Dogu; Halit Karaca; Mustafa Dikilitas; Ahmet Oztürk; Metin Ozkan; Bünyamin Kaplan
Journal:  Ann Thorac Med       Date:  2013-04       Impact factor: 2.219

8.  Clinical features and prognostic factors in elderly koreans with advanced non-small-cell lung cancer in a tertiary referral hospital.

Authors:  Seo Woo Kim; Mi Yeon Kim; Yoon Pyo Lee; Yon Ju Ryu; Seok Jeong Lee; Jin Hwa Lee; Jung Hyun Chang; Sung Shine Shim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-08-30

9.  Prognostic value of pretreatment platelet counts in lung cancer: a systematic review and meta-analysis.

Authors:  Yuan Yuan; Hai Zhong; Liang Ye; Qian Li; Surong Fang; Wei Gu; Yingying Qian
Journal:  BMC Pulm Med       Date:  2020-04-20       Impact factor: 3.317

10.  A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease.

Authors:  Jörg Menche; Amitabh Sharma; Michael H Cho; Ruth J Mayer; Stephen I Rennard; Bartolome Celli; Bruce E Miller; Nick Locantore; Ruth Tal-Singer; Soumitra Ghosh; Chris Larminie; Glyn Bradley; John H Riley; Alvar Agusti; Edwin K Silverman; Albert-László Barabási
Journal:  BMC Syst Biol       Date:  2014-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.